Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PULTAR

Financiado

Cerrado

Delivery of PULmonary Therapeutics through TARgetted Delivery using Phononics

According to the WHO 235 million people suffer from asthma and 64M people have chronic obstructive pulmonary disease, leading to 3M deaths per year worldwide. The cost of treating patients with all forms of lung disease is ~ €380B... ver más

31/12/2016

UNIVERSITY OF GLAS...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITY OF GLASGOW No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2016-12-31

ERC-PoC-2014: ERC Proof of Concept Grant Scope:Objectives

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UNIVERSITY OF GLASGOW

149.79K€ | Lider

KOROTT

250.93K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SONOPHARMAGEN Remote controlling biological systems by sonopharmacology an... 3M€ Cerrado

MULTraSonicA Multiscale modeling and simulation approaches for biomedical... 2M€ Cerrado

RESPIRNA REpurposing lung Surfactant Protein B for Inhalation therapy... 2M€ Cerrado

PID2019-106199RB-C22 DISEÑO, FABRICACION Y CARACTERIZACION DE UN DISPOSITIVO BASA... 145K€ Cerrado

NUEVAS MODALIDADES TERAPÉUTICAS PARA EL TRATA... NUEVAS MODALIDADES TERAPÉUTICAS PARA EL TRATAMIENTO DE LA EN... 3M€ Cerrado

TheraCav Harnessing Cavitation for Therapy 1M€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2015-06-15
Fecha Fin: 2016-12-31

Líder del proyecto

UNIVERSITY OF GLASGOW No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto According to the WHO 235 million people suffer from asthma and 64M people have chronic obstructive pulmonary disease, leading to 3M deaths per year worldwide. The cost of treating patients with all forms of lung disease is ~ €380B p.a., leading to the loss of >50M DALYS. Generally, patients with such respiratory diseases are treated by inhalation of medicines within aerosols, where the therapy (including medicine or biologics used in gene therapy) can be targeted directly to the lung. The accepted wisdom is that such pulmonary delivery requires aerosol droplet sizes of between 1 and 5 μm. We have now shown that by using a new ultrasonic technology, we can create monodisperse aerosol droplets, which could be used for therapeutic delivery of medicines, genes and RNA to specific regions in the lungs. In one strand of the work we aim to demonstrate that this precise nebulisation technology improves the efficacy of treatment through enhanced drug uptake. In a second strand, we will demonstrate selective targeting of different tissue types in the lungs. For example, the epithelium in cystic fibrosis patients is currently extremely difficult to access leading to limitations in the amount and quality of data obtained for pre-clinical and clinical gene therapies. Similarly, targeting vascular cells is an appealing treatment for patients with pulmonary arterial hypertension, although, again, effective delivery necessitates that the therapeutic system transits defined and substantial anatomical barriers. The overall aim is to demonstrate that this new technology can define routes to new therapies, improve clinical outcomes and reduce healthcare costs. To achieve this we will develop a prototype nebuliser based upon proprietary technology and show that different medicines and gene therapies can be delivered effectively to the lungs of a model mouse. We will also start to build a commercial team and work closely with industry to deliver impact and innovation to the market.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores